Intraperitoneal chemotherapy in older women with epithelial ovarian cancer

Journal of Geriatric Oncology

Volumn 3, Issue 3, 2012, Pages 189-195

  O'Cearbhaill, Roisin ^a,b   Li, Daneng ^a,b   Shi, Weiji ^a   Thaler, Howard ^a   Sabbatini, Paul J ^a,b   Konner, Jason ^a,b   Hensley, Martee L ^a,b   Aghajanian, Carol A ^a,b   Lichtman, Stuart M ^a,b   Tew, William P ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Intraperitoneal chemotherapy; Older patients; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ABDOMINAL PAIN; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CATHETER INFECTION; CATHETER OCCLUSION; CLINICAL EVALUATION; COMORBIDITY; CONSOLIDATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERANCE; ELECTROLYTE DISTURBANCE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HEARING IMPAIRMENT; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; IATROGENIC DISEASE; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PERITONEAL CATHETER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; STROKE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK;

EID: 84862794498     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2012.02.007     Document Type: Article

References (31)

1. Chiara S., Lionetto R., Vincenti M., Bruzzone M., Nobile M.T., Gadducci A., et al. Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. Crit Rev Oncol Hematol 2001, 37:27-34.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Ries L.A. Ovarian cancer. Survival and treatment differences by age. Cancer 1993, 71:524-529.
4. Thigpen T., Brady M.F., Omura G.A., Creasman W.T., McGuire W.P., Hoskins W.J., et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993, 71:606-614.
5. Winter W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:3621-3627.
6. Kosary C.L. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994, 10:31-46.
7. Gershenson D.M., Mitchell M.F., Atkinson N., Silva E.G., Burke T.W., Morris M., et al. Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer 1993, 71:638-643.
8. Moore D.H., Kauderer J.T., Bell J., Curtin J.P., Van Le L. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol 2004, 94:368-374.
9. Uyar D., Frasure H.E., Markman M., von Gruenigen V.E. Treatment patterns by decade of life in elderly women (> or =70years of age) with ovarian cancer. Gynecol Oncol 2005, 98:403-408.
10. Sundararajan V., Hershman D., Grann V.R., Jacobson J.S., Neugut A.I. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 2002, 20:173-178.
11. Edmonson J.H., Su J., Krook J.E. Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group studies. Cancer 1993, 71:615-617.
12. Bicher A., Sarosy G., Kohn E., Adamo D.O., Davis P., Jacob J., et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer 1993, 71:594-600.
13. Eisenhauer E.L., Tew W.P., Levine D.A., Lichtman S.M., Brown C.L., Aghajanian C., et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol 2007, 106:381-387.
14. Kothari R., Nagel C., Koopmeiners J.S., Ivy J.J., Geller M., Salani R., et al. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer. Gynecol Oncol 2010, 119:491-495.
15. Pignata S., Vermorken J.B. Ovarian cancer in the elderly. Crit Rev Oncol Hematol 2004, 49:77-86.
16. Matulonis U.A., Krag K.J., Krasner C.N., Atkinson T., Horowitz N.S., Lee H., et al. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecol Oncol 2009, 112:394-399.
17. Repetto L., Fratino L., Audisio R.A., Venturino A., Gianni W., Vercelli M., et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002, 20:494-502.
18. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43.
19. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996, 335:1950-1955.
20. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:1001-1007.
21. NCI Clinical Announcement: Intraperitoneal chemotherapy for ovarian cancer Available at:, Last accessed: November 9, 2011. http://www.gog.org/IPChemoEd/clinicalann.pdf.
22. Ferguson S.E., Black D., Chi D.S. Toxicities of modified outpatient regimen of IV/Ip Paclitaxel and Ip Cisplatin in women with newly diagnosed ovarian cancer: 0123. Int J Gynecol Cancer 2006, 16:635.
23. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
24. Nordin A.J., Chinn D.J., Moloney I., Naik R., de Barros Lopes A., Monaghan J.M. Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol Oncol 2001, 81:447-455.
25. Bruchim I., Altaras M., Fishman A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol 2002, 86:274-278.
26. Hurria A., Brogan K., Panageas K.S., Panageas K.S., Pearce C., Norton L., et al. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging 2005, 22:785-791.
27. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003, 1:18-24.
28. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000, 5:224-237.
29. Hurria A., Togawa K., Mohile S.G., Owusu C., Klepin H.D., Gross C., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective 500 patient multicenter study. J Clin Oncol 2010, 28:9001. (Meeting Abstracts).
30. Rockwood K., Stadnyk K., MacKnight C., McDowell I., Hébert R., Hogan D.B. A brief clinical instrument to classify frailty in elderly people. Lancet 1999, 353:205-206.
31. Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998, 16:1582-1587.